分子細胞遺伝学の世界市場予測（～2021）：製品別（キット、試薬、プローブ、消耗品、ソフトウェア、サービス）、技術別（ハイブリダイゼーション法(In-Situ)、蛍光染色体ハイブリッド形成(FISH)、比較ゲノムハイブリダイゼーション）、用途別（がん、遺伝）、エンドユーザー別（研究室、研究機関）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 MARKETS COVERED 14
1.3.1 YEARS CONSIDERED FOR THE STUDY 14
1.4 CURRENCY 15
1.5 LIMITATIONS 15
1.6 STAKEHOLDERS 15
2 RESEARCH METHODOLOGY 16
2.1 SECONDARY DATA 17
2.1.1 KEY DATA FROM SECONDARY SOURCES 17
2.2 PRIMARY DATA 18
2.2.1 KEY DATA FROM PRIMARY SOURCES 19
2.3 MARKET SIZE ESTIMATION 20
2.3.1 BOTTOM-UP APPROACH 20
2.3.2 TOP-DOWN APPROACH 21
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.5 ASSUMPTIONS FOR THE STUDY 23
3 EXECUTIVE SUMMARY 24
3.1 CONCLUSION 29
4 PREMIUM INSIGHTS 30
4.1 MOLECULAR CYTOGENETICS: MARKET OVERVIEW 30
4.2 GEOGRAPHIC ANALYSIS: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUES 31
4.3 MOLECULAR CYTOGENETICS MARKET SIZE, BY APPLICATION 32
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 MARKET DRIVERS 36
5.2.1.1 Increasing incidence of genetic disorders and cancer 36
5.2.1.2 Growing focus on targeted cancer treatment 37
5.2.1.3 Increasing aging population and subsequent rise in prevalence of chronic diseases 38
5.2.1.4 Increasing penetration of molecular cytogenetics in clinical pathological testing 38

5.2.2 MARKET RESTRAINTS 39
5.2.2.1 High cost of advanced instruments 39
5.2.2.2 Unfavourable reimbursement scenario 39
5.2.3 MARKET OPPORTUNITIES 40
5.2.3.1 Untapped emerging markets in Asia 40
5.2.4 MARKET TRENDS 40
5.2.4.1 Transition from FISH to Array-based techniques 40
6 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT 41
6.1 INTRODUCTION 42
6.2 KITS & REAGENTS 44
6.2.1 TESTING KITS 45
6.2.2 PROBES 46
6.2.3 FLUORESCENT AFFINITY REAGENTS 46
6.2.4 OTHER KITS & REAGENTS 47
6.3 INSTRUMENTS 48
6.4 CONSUMABLES 49
6.5 SOFTWARE & SERVICES 49
7 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE 51
7.1 INTRODUCTION 52
7.2 COMPARATIVE GENOMIC HYBRIDIZATION 53
7.2.1 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION 55
7.2.2 STANDARD COMPARATIVE GENOMIC HYBRIDIZATION 56
7.3 FLUORESCENCE IN SITU HYBRIDIZATION 57
7.4 IN SITU HYBRIDIZATION 58
7.5 OTHER TECHNIQUES 59
8 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION 60
8.1 INTRODUCTION 61
8.2 GENETIC DISORDERS 62
8.3 CANCER 63
8.4 PERSONALIZED MEDICINE 64
8.5 OTHER APPLICATIONS 65
9 MOLECULAR CYTOGENETICS MARKET, BY END USER 66
9.1 INTRODUCTION 67
9.2 CLINICAL & RESEARCH LABORATORIES 68
9.3 ACADEMIC RESEARCH INSTITUTES 69
9.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 70
9.5 OTHER END USERS 71
10 MOLECULAR CYTOGENETICS MARKET, BY REGION 72
10.1 INTRODUCTION 73
10.2 NORTH AMERICA 75
10.2.1 U.S. 80
10.2.2 CANADA 83
10.3 EUROPE 85
10.4 ASIA 88
10.4.1 CHINA 93
10.4.2 JAPAN 96
10.4.3 INDIA 99
10.4.4 ROA 102
10.5 REST OF THE WORLD (ROW) 105
11 COMPETITIVE LANDSCAPE 109
11.1 INTRODUCTION 109
11.2 STRATEGIC OVERVIEW 109
11.3 MARKET SHARE ANALYSIS 110
11.4 COMPETITIVE SITUATION AND TRENDS 111
11.4.1 COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS 112
11.4.2 NEW PRODUCT LAUNCHES 113
11.4.3 ACQUISITIONS 114
11.4.4 EXPANSIONS 114
11.4.5 OTHER DEVELOPMENTS 115
12 COMPANY PROFILES 116
(Company at a Glance, Recent Financials, Products & Services, Strategies & Insights, & Recent Developments)*
12.1 INTRODUCTION 116
12.2 ABBOTT LABORATORIES, INC. 117
12.3 AGILENT TECHNOLOGIES, INC. 119
12.4 APPLIED SPECTRAL IMAGING 122
12.5 BIO-RAD LABORATORIES, INC. 123
12.6 DANAHER CORPORATION 125
12.7 ILLUMINA, INC. 127
12.8 OXFORD GENE TECHNOLOGY (OGT) 129
12.9 PERKINELMER, INC. 131
12.10 F. HOFFMANN-LA ROCHE LTD. 133
12.11 THERMO FISHER SCIENTIFIC INC. 136
*Details on company at a glance, recent financials, products & services, strategies & insights, & recent developments might not be captured in case of unlisted companies.
13 APPENDIX 138
13.1 INSIGHTS OF INDUSTRY EXPERTS 138
13.2 DISCUSSION GUIDE 139
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 142
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 144
13.5 AVAILABLE CUSTOMIZATIONS 146
13.6 RELATED REPORTS 146
13.7 AUTHOR DETAILS 147